“This study highlights that a substantial number of patients with localized CRC undergoing curative-intent treatment with CAPOX do not complete the planned cycles of chemotherapy because of toxicity ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

Colorectal cancer is the third-leading cause of cancer death for both men and women in the U.S., according to the American ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

All eyes are now on the readout of a second phase 3 trial called GLOW, looking at the addition of zolbetuximab to another chemo regimen called CAPOX in a similar population of treatment-naïve ...

which assessed zolbetuximab plus a chemotherapy regimen of capecitabine and oxaliplatin (CAPOX). Vyloy was shown to significantly increase progression-free survival (PFS) compared to chemotherapy ...

The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy as a new standard ... with capecitabine and oxaliplatin (CAPOX) compared to placebo plus CAPOX as first-line ...

GEMSTONE-303 is a Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of sugemalimab in combination with capecitabine and oxaliplatin (CAPOX) compared to ...

GEMSTONE-303 is a Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of sugemalimab in combination with capecitabine and oxaliplatin (CAPOX ... In ...